Sökning: "Klinisk farmakologi"

Visar resultat 6 - 10 av 165 avhandlingar innehållade orden Klinisk farmakologi.

  1. 6. On the Prediction of Warfarin Dose

    Författare :Niclas Eriksson; Mia Wadelius; Lars Wallentin; Lars Berglund; Patrik Magnusson; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Warfarin; pharmacogenetics; prediction models; Dosing algorithm; GWAS; VKORC1; CYP2C9; Clinical Pharmacology; Klinisk farmakologi;

    Sammanfattning : Warfarin is one of the most widely used anticoagulants in the world. Treatment is complicated by a large inter-individual variation in the dose needed to reach adequate levels of anticoagulation i.e. INR 2. LÄS MER

  3. 7. Nucleoside analoge cytotoxicity-focus on enzyme regulation, metabolism, and mechanisms of resistance

    Författare :Anna Fyrberg; Kourosh Lotfi; Curt Peterson; Freidoun Albertioni; Francoise Bontemps; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacology; Farmakologi;

    Sammanfattning : The aim of this thesis was to determine the role of nucleoside analog activating and deactivating enzymes in nucleoside analog metabolism and resistance development. Nucleoside analogs are anti-cancer drogs and are often used to treat different leukemias, attributably to presence of high levels of nucleoside analog activating enzymes in hematopoietic cells. LÄS MER

  4. 8. Preclinical Development of New Alkylating Oligopeptides for Cancer Therapy

    Författare :Joachim Gullbo; Rolf Larsson; Peter Nygren; Staffan Eriksson; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Pharmacology; pharmacology; oncology; chemistry; Melphalan derivatives; Farmakologi; Pharmacological research; Farmakologisk forskning;

    Sammanfattning : Oligopeptides can be used to carry cytotoxic agents in cancer chemotherapy, using tumour-associated proteins as the molecular target for selectivity. During the seventies and eighties Peptichemio, a cocktail of six alkylating oligopeptides carrying m-L-sarcolysin, was investigated in a wide variety of human malignancies. LÄS MER

  5. 9. Integrating Efficacy and Toxicity in Preclinical Anticancer Drug Development : Methods and Applications

    Författare :Caroline Haglund; Elin Lindhagen; Rolf Larsson; Anna Åleskog; Sigurd Vitols; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Anticancer drugs; In vitro assays; Toxicity testing; Haematological toxicity; Primary tumour cells; Species difference; Clinical pharmacology; Klinisk farmakologi; Clinical Pharmacology; Klinisk farmakologi;

    Sammanfattning : Preclinical testing is an important part of cancer drug development. The aim of this thesis was to establish and evaluate preclinical in vitro methods useful in the development of new anticancer drugs. In paper I, the development of non-clonogenic assays (FMCA-GM) using CD34+ stem cells for assessment of haematological toxicity was described. LÄS MER

  7. 10. Risk Talk : On Communicating Benefits and Harms in Health Care

    Författare :Mikael Hoffmann; Karin Kjellgren; Mats Hammar; Johan Ahlner; Bengt Mattson; Linköpings universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; risk; communication; menopause; hormone replacement therapy; physician-patient relations; Clinical pharmacology; Klinisk farmakologi;

    Sammanfattning : One of the most critical elements in empowering the patient, and ensuring concordance, is communication of the possible benefits and harms of different actions in health care. Risk assessment is a complex task due both to the different interpretations of the concept of risk, and the common lack of hard facts. LÄS MER